Atossa Therapeutics, Inc. announced that the first patient has been dosed with Atossa's proprietary Selective Estrogen Receptor Modulator (SERM), (Z)-endoxifen, in the Re-Evaluating Conditions for Active Surveillance Suitability as Treatment: Ductal Carcinoma In Situ (RECAST DCIS) study. RECAST DCIS is an ongoing Phase 2 platform study designed to offer women diagnosed with DCIS six months of neoadjuvant endocrine therapy with the intent of determining their suitability for long-term active surveillance without surgery. A short 'explainer' video about Ductal Carcinoma in Situ and the RECAST DCIS study can be found here: DCIS Video Explainer.

Studies show that recurrence of DCIS can occur in up to 1 in 3 patients following treatment. About (Z)-Endoxifen (Z)-endoxifan is the most active metabolite of the FDA approved Selective Estrogen Receptor modulator (SERM), tamoxifen. Studies have demonstrated that the therapeutic effects of tamoxifen are driven in a concentration-dependent manner by (Z)-endoxifEN.